Who are Placebo to Telmisartan's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): RAS Inhibitors, placebo/valsartan, Valsartant treatment, losartan/amlodpine, VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE, Cozzar tablet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-to-telmisartan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo to Telmisartan — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo to Telmisartan (Placebo to Telmisartan) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker (ARB). Area: Cardiovascular.

marketed Angiotensin II receptor blocker (ARB) AT1 receptor (Angiotensin II type 1 receptor) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Placebo to Telmisartan (Placebo to Telmisartan) — Novartis. Telmisartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo to Telmisartan TARGET	Placebo to Telmisartan	Novartis	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
RAS Inhibitors	RAS Inhibitors	Shenzhen Second People's Hospital	marketed	ACE inhibitor or Angiotensin II receptor blocker (ARB)	ACE enzyme or Angiotensin II Type 1 receptor (AT1R)
placebo/valsartan	placebo/valsartan	Medical University of Silesia	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
Valsartant treatment	Valsartant treatment	University Hospital, Grenoble	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
losartan/amlodpine	losartan/amlodpine	University of Pavia	marketed	Angiotensin II receptor blocker (ARB) / Calcium channel blocker (CCB)	Angiotensin II receptors (AT1) and L-type calcium channels
VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE	VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE	Novartis	marketed	Angiotensin II receptor blocker (ARB) + thiazide diuretic	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter (NCC)
Cozzar tablet	Cozzar tablet	Chong Kun Dang Pharmaceutical	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (angiotensin II type 1 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker (ARB) class)

Chong Kun Dang Pharmaceutical · 2 drugs in this class
Baker Heart and Diabetes Institute · 2 drugs in this class
Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
Lee's Pharmaceutical Limited · 2 drugs in this class
Bristol-Myers Squibb · 1 drug in this class
Guangdong Provincial People's Hospital · 1 drug in this class
Fifth Affiliated Hospital, Sun Yat-Sen University · 1 drug in this class
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 1 drug in this class
Bayer · 1 drug in this class
Arbor Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to Telmisartan — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-telmisartan. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab